Epigenetics in ovarian cancer: premise, properties, and perspectives.
Publication/Presentation Date
7-31-2018
Abstract
Malignant ovarian tumors bear the highest mortality rate among all gynecological cancers. Both late tumor diagnosis and tolerance to available chemical therapy increase patient mortality. Therefore, it is both urgent and important to identify biomarkers facilitating early identification and novel agents preventing recurrence. Accumulating evidence demonstrates that epigenetic aberrations (particularly histone modifications) are crucial in tumor initiation and development. Histone acetylation and methylation are respectively regulated by acetyltransferases-deacetylases and methyltransferases-demethylases, both of which are implicated in ovarian cancer pathogenesis. In this review, we summarize the most recent discoveries pertaining to ovarian cancer development arising from the imbalance of histone acetylation and methylation, and provide insight into novel therapeutic interventions for the treatment of ovarian carcinoma.
Volume
17
Issue
1
First Page
109
Last Page
109
ISSN
1476-4598
Published In/Presented At
Yang, Q., Yang, Y., Zhou, N., Tang, K., Lau, W. B., Lau, B., Wang, W., Xu, L., Yang, Z., Huang, S., Wang, X., Yi, T., Zhao, X., Wei, Y., Wang, H., Zhao, L., & Zhou, S. (2018). Epigenetics in ovarian cancer: premise, properties, and perspectives. Molecular cancer, 17(1), 109. https://doi.org/10.1186/s12943-018-0855-4
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
30064416
Department(s)
Administration and Leadership
Document Type
Article